SNPX | Synaptogenix, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.01 - 3.18
52 Week Range	2.7200 - 11.48
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	16,689
Average Volume	38,301
Shares Outstanding	1,314,310
Market Cap	4,034,932
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-08

Valuation
Profitability
Growth
Health
P/E Ratio	0.30
Forward P/E Ratio	N/A
EPS	10.27
1YR Price Target	14.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	5
Country	USA
Website	SNPX

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

SNPX's peers: ANVS, CYTH, RVPH, INMB, ALZN

*Chart delayed

Analyzing fundamentals for SNPX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see SNPX Fundamentals page.

Watching at SNPX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SNPX Technicals page.